Related Experiment Videos
Identification of a new missense mutation in MyBP-C associated with hypertrophic cardiomyopathy
J C Moolman-Smook1, B Mayosi, P Brink
1University of Stellenbosch and South African Medical Research Council Centre for Molecular and Cellular Biology, Department of Medical Physiology and Biochemistry, Tygerberg.
Insights
Hypertrophic cardiomyopathy (HCM) is linked to cardiac myosin binding protein C (MyBP-C) gene mutations. A novel Arg654His missense mutation in MyBP-C was found in a South African family, with varied disease severity.
Area of Science:
- Cardiovascular Genetics
- Molecular Cardiology
- Genetic Disease
Background:
- Hypertrophic cardiomyopathy (HCM) is a primary cardiac condition characterized by myocardial hypertrophy.
- Genetic defects in sarcomeric protein genes, including cardiac myosin binding protein C (MyBP-C), are primary causes of HCM.
- Previous studies identified splice site and duplication mutations in MyBP-C associated with HCM.
Observation:
- Mutation screening of a South African HCM population identified a novel missense mutation, Arg654His, in the MyBP-C gene.
- This mutation was present in a proband and three adult children, but only the proband exhibited significant disease.
- The Arg654His mutation is located outside the myosin and titin binding domains of MyBP-C.
Findings:
- This study reports the first disease-associated missense mutation in MyBP-C that does not involve the myosin or titin binding domains.
- The Arg654His mutation demonstrates variable expressivity within a family, suggesting other genetic or environmental factors influence HCM phenotype.
- The identification of this novel mutation expands the spectrum of MyBP-C mutations linked to hypertrophic cardiomyopathy.
Implications:
- This finding contributes to understanding the genetic basis of hypertrophic cardiomyopathy and the role of MyBP-C.
- Further research is needed to elucidate the functional consequences of the Arg654His mutation and its impact on cardiac function.
- The variable expressivity highlights the complexity of HCM pathogenesis and the need for personalized risk assessment.
Abstract:
Hypertrophic cardiomyopathy is a primary cardiac disease, characterised by idiopathic myocardial hypertrophy, and is caused by defects in sarcomeric protein encoding genes. One of these genes is cardiac myosin binding protein C (MyBP-C), in which a number of splice site and duplication mutations causing HCM have been described. During mutation screening of a South African HCM population by PCR-SSCP, a missense mutation, Arg654His, was detected in one proband. Although the mutation was present in his three adult children, only the proband himself was markedly affected. This is the first report of a disease associated missense mutation in MyBP-C which does not affect the myosin or titin binding domains.